Key facts
- Profluent’s last known valuation is $525.0M (Nov 2025).
- It has raised $150.0M across 2 recorded rounds; the latest was Early Stage VC (Series B) ($106.0M) in Nov 2025.
- Notable investors include Insight Partners (New York), Spark Capital, Jeff Dean, Altimeter Capital Management, AIX Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Profluent
Funding rounds
2 roundsAbout Profluent
Developer of artificial intelligence-driven models designed to create and validate novel proteins for biomedicine. The company's platform leverages deep generative models trained on billions of biological sequences, enabling the healthcare industry to optimize across diverse functional attributes in enzymes, antibodies, gene editors, and peptides.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2022
- Employees
- 50
- Website
- profluent.bio/
- Ownership
- Privately Held (backing)
Profluent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Profluent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Profluent in its N-PORT filings yet. We sweep new filings monthly.